Hanmi Pharm. Co., Ltd. – Company Intelligence Brief

1. Business Overview

Hanmi Pharmaceutical Co., Ltd. is a South Korean pharmaceutical company listed on the Korean stock exchange (code: 128940) with a market capitalization of approximately KRW 6.6 trillion. Based on the consolidated financial statement data (15th fiscal year, ending December 31, 2024), the company operates in the pharmaceutical manufacturing and distribution sector.

[TRANSLATION NOTE: Detailed business segment information and product portfolio descriptions were not included in the provided DART filing excerpt and may require reference to Korean-language business reports for complete accuracy.]

2. Financial Trend

Hanmi Pharm demonstrates modest but stable growth trajectory. Revenue increased slightly from KRW 1,490.9 billion (FY2023) to KRW 1,495.5 billion (FY2024), representing a marginal 0.3% year-over-year growth. However, this follows stronger 12.0% growth in the prior period (FY2022 to FY2023).

Operating profit margins show signs of compression. Operating income declined from KRW 220.7 billion (14.8% margin) in FY2023 to KRW 216.2 billion (14.5% margin) in FY2024. Net income also decreased from KRW 165.4 billion to KRW 140.4 billion, representing a 15.1% decline despite flat revenues, suggesting rising operating costs or non-operating expenses.

The balance sheet remains healthy with a strong equity position. Total assets grew 6.4% to KRW 2,021 billion, while total liabilities decreased slightly to KRW 780.1 billion. The debt-to-equity ratio improved significantly to 0.63x (from 0.73x), indicating conservative leverage. Retained earnings grew from KRW 582.0 billion to KRW 680.9 billion, demonstrating continued profitability despite near-term margin pressure.

3. Ownership Structure

[TRANSLATION NOTE: Ownership structure and foreign ownership percentage data were not included in the financial statement excerpts provided. This information typically appears in separate sections of DART filings (주식등의소유현황) and would require access to those specific Korean-language disclosure documents for accurate reporting.]

4. Key Risks

Margin Compression Risk: The company faces declining profitability despite stable revenues. Operating margin contracted by 30 basis points, and net margin fell from 11.1% to 9.4% year-over-year, suggesting cost control challenges or pricing pressure that warrant monitoring.

Growth Stagnation Risk: Revenue growth decelerated sharply from 12.0% (FY2022-2023) to just 0.3% (FY2023-2024), indicating potential market saturation, competitive pressures, or pipeline development challenges in a pharmaceutical sector that typically requires continuous innovation.

5. Investment Consideration

Hanmi Pharm presents as a financially stable mid-tier Korean pharmaceutical company with strong balance sheet fundamentals but faces near-term headwinds from margin compression and revenue growth deceleration that require clarification on pipeline development and cost management strategies.